Celularity Inc. Form 8-K Summary
Business context and reporting period
Celularity Inc. filed a Form 8-K dated May 16, 2022, under Items 2.02 and 9.01. The filing references a press release announcing financial results as of and for the quarter ended March 31, 2022. The referenced press release was furnished as Exhibit 99.1, but its financial content is not included in the provided filing text.
Financial results and key metrics
The provided filing text does not provide clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics. Investors must review Exhibit 99.1 or the related quarterly filing for these amounts.
Material changes versus the prior comparable period
No specific year-over-year or sequential financial changes are stated in the provided text.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided text. The filing states that the Item 2.02 information and Exhibit 99.1 are furnished, not filed for purposes of Section 18 of the Exchange Act, and are not incorporated by reference except where expressly stated.
Key facts to verify
- Obtain and review Exhibit 99.1 for the March 31, 2022 quarterly financial results.
- Verify revenue, net loss, cash position, operating cash burn, debt, and liquidity measures.
- Compare the quarter’s results with the prior-year and immediately preceding quarters.
- Review any management guidance, financing plans, going-concern disclosures, and clinical or commercial program updates in the complete earnings materials.
- Note that Celularity’s Class A common stock traded under “CELU” and its warrants under “CELUW” on Nasdaq as of the filing date.